Search results
Results from the WOW.Com Content Network
The study found a 39% lower HIV infection rate in women using 1% tenofovir gel compared with women using a placebo gel. In addition, tenofovir gel was shown to be safe as tested. [ 21 ] The results of the CAPRISA 004 trial provide statistically significant evidence that ARVs, topically applied to the vaginal mucosa, can offer protection against ...
The National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (NCHHSTP), formerly the National Center for HIV, STD, and TB Prevention (NCHSTP) is a part of the Centers for Disease Control and Prevention and is responsible for public health surveillance, prevention research, and programs to prevent and control human immunodeficiency virus (HIV) infection and acquired ...
The management of HIV/AIDS normally includes the use of multiple antiretroviral drugs as a strategy to control HIV infection. [1] There are several classes of antiretroviral agents that act on different stages of the HIV life-cycle. The use of multiple drugs that act on different viral targets is known as highly active antiretroviral therapy ...
For premium support please call: 800-290-4726 more ways to reach us
Please help improve this article by adding citations to reliable sources. Unsourced material may be challenged and removed. Unsourced material may be challenged and removed. Find sources: "List of antiretroviral fixed-dose combinations" – news · newspapers · books · scholar · JSTOR ( January 2021 ) ( Learn how and when to remove this ...
It was approved for PrEP against HIV infection in the United States in 2012. [17] The CDC recommends PrEP be considered for the following high-risk groups: [18] Individuals in an ongoing sexual relationship with an HIV-positive partner; Gay or bisexual men who either have had anal sex without a condom or been diagnosed with an STD in the past ...
Employers who challenged some federal health insurance requirements cannot be forced to provide no-cost coverage for certain types of preventive care, including HIV prep and some kinds of cancer ...
Already approved as a treatment for multi-drug resistant HIV—costing approximately $42,250 for the first year in the U.S.—lenacapavir has also shown strong efficacy in preventing HIV infection during recent clinical trials. Gilead is actively seeking regulatory approvals for its preventive use worldwide. [56]